Differences

This shows you the differences between two versions of the page.

--- home:protocol:olmesartan:kidney_disease [08.13.2019] – [Animal studies] sallieq
+++ home:protocol:olmesartan:kidney_disease [08.13.2019] – [Subclinical kidney infection] sallieq
@@ Line 7: / Line 7: @@
-===== Subclinical kidney infection =====
-Subclinical - that is to say, undetected or undetectable - kidney disease is common in patients with [[home:pathogenesis:th1spectrum|Th1 diseases]], and this is no less true of MP patients. Inflammation in the kidney and liver tend to be “silent.” Before beginning the MP, the kidneys are inflamed because they are infected with the [[home:pathogenesis::microbiota|Th1 pathogens]]. Patients tend to be largely unaware of the problem because their immune system, which has been weakened by the pathogens, doesn’t kill enough of the pathogens to cause a rise in bacterial byproducts that would be picked up on a blood test.
-Once patients activate the [[home:pathogenesis:innate_immunity|innate immune system]] with olmesartan and begin rapidly killing the Th1 pathogens, the resulting immunopathology causes a rise in bacterial death, the effects of which are finally high enough to show up on lab tests.

home/protocol/olmesartan/kidney_disease.txt · Last modified: 09.14.2022 by 127.0.0.1